Bedrijfsoverzicht
Exact Sciences Corporation is a leading provider of cancer screening and diagnostic test products, with its core operations focused on the United States and international markets. The company primarily offers Cologuard, a non-invasive stool-based DNA screening test designed to detect specific DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer conditions, alongside the Cologuard Plus Test. Operating within the healthcare sector, specifically the diagnostics and research industry, the firm leverages advanced molecular biology to identify early-stage malignancies before symptoms arise. The company's current market capitalization stands at $20.03 billion, supported by annual revenue of $3.25 billion and a workforce of 7,100 employees. These valuation and revenue figures indicate that Exact Sciences has established a significant position in the oncology diagnostics landscape, reflecting strong market demand for non-invasive colorectal cancer screening solutions that complement traditional colonoscopy procedures.
Financiële gezondheid
The company reported trailing twelve-month revenue of $3.25 billion, yet generated a net income loss of approximately $208 million, while its EBITDA reached $71.46 million. The substantial gap between the positive revenue of $3.25 billion and the negative net income of $207.95 million reveals a cost structure where operating expenses, likely driven by research and development or sales and marketing costs, significantly outweigh gross profits before interest and taxes. Despite the net loss, the company maintains robust free cash flow of $281.87 million, which provides essential financial flexibility to fund ongoing operations, invest in new technologies, or manage debt obligations without relying solely on external financing. The gross margin stands at an impressive 69.7%, indicating high profitability on each unit sold before operating expenses, whereas the operating margin is negative at -9.3% and the profit margin is -6.4%, highlighting that operating costs are currently eroding the bottom line. On the balance sheet, the company holds $964.71 million in cash against total debt of $2.53 billion, resulting in a debt-to-equity ratio of 105.57%, which characterizes a highly leveraged financial structure rather than a conservative one. The current ratio of 2.43 suggests that the company possesses sufficient short-term assets to cover its short-term liabilities, indicating a healthy liquidity position despite the leverage. Furthermore, the return on equity is negative at -8.7% and the return on assets is -1.6%, metrics that collectively reveal that management has not yet generated returns on the capital invested or utilized assets effectively to produce profits in the current fiscal period.
Waarderingsbeoordeling
The valuation metrics present a complex picture, with a forward P/E ratio of 55.22 listed while the trailing P/E ratio is N/A due to the recent net loss. The absence of a trailing P/E and the high forward P/E imply that the market is pricing in a significant expected turnaround in earnings trajectory, as current earnings are insufficient to support a traditional trailing multiple. The price-to-book ratio is 8.34, which indicates that the market assigns a substantial premium to the company's equity value relative to its book value, suggesting high expectations for future growth or intangible asset value. Alternative valuation metrics such as the price-to-sales ratio of 6.17 and an EV/EBITDA of 302.23 further suggest that the market is willing to pay a high multiple for sales, reflecting confidence in the scalability of its diagnostic testing model. In terms of price volatility, the stock trades with a beta of 1.44, meaning its price movements are expected to be more volatile than the broader market, amplifying gains and losses relative to the S&P 500. The 52-week high is $104.98 and the 52-week low is $38.81, defining a trading range where the current price dynamics reflect the market's reassessment of the company's earnings potential.
Growth & Income
Exact Sciences has demonstrated aggressive expansion with revenue growth of 23.1% year-over-year, while earnings growth is N/A due to the reported net loss. The disparity between strong revenue growth of 23.1% and zero earnings growth indicates that the company is prioritizing top-line expansion through market penetration and product adoption, even at the expense of immediate profitability. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, which means all available earnings are retained and reinvested into research and development, manufacturing capacity, or market expansion rather than being distributed to shareholders. This reinvestment strategy is typical for growth-oriented biotechnology firms that seek to capitalize on future market opportunities rather than providing current income. Overall, the growth and income profile is defined by rapid revenue acceleration and a complete reliance on internal capital generation to fund operations and future growth initiatives in the competitive diagnostic testing sector.